Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.86 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.86 |
| ▸ | MEN1 | O00255 | 2/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.79 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.66 |
| ▸ | HTR1A | P08908 | 2/20 | 0.66 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.66 |
| ▸ | DRD1 | P21728 | 2/20 | 0.66 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.66 |
| ▸ | DRD3 | P35462 | 2/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.66 |
| ▸ | BCL2 | P10415 | 1/20 | 0.66 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norchlorcyclizine SCHEMBL588655 | 1.00 | CYP2D6 (0.86) | CYP2D6CYP19A1MEN1KMT2AOPRD1 | |
| Norchlorcyclizine SCHEMBL467086 | 1.00 | CYP2D6 (0.86) | CYP2D6CYP19A1MEN1KMT2AOPRD1 | |
| Norchlorcyclizine SCHEMBL4649874 | 0.98 | CYP2D6 (0.83) | CYP2D6CYP19A1MEN1KMT2AOPRD1 | |
| Norchlorcyclizine SCHEMBL588155 | 0.98 | CYP2D6 (0.83) | CYP2D6CYP19A1MEN1KMT2AOPRD1 | |
| Norchlorcyclizine SCHEMBL7139140 | 0.97 | CYP2D6 (0.81) | CYP2D6CYP19A1MEN1KMT2AOPRD1 | |
| SCHEMBL5363117 | 0.94 | CYP2D6 (0.76) | CYP2D6CYP19A1MEN1KMT2AOPRD1 | |
| SCHEMBL1137956 | 0.93 | CYP2D6 (1.00) | CYP2D6CYP19A1MEN1KMT2AOPRD1 | |
| Norchlorcyclizine SCHEMBL7989702 | 0.92 | CYP2D6 (0.73) | CYP2D6CYP19A1MEN1KMT2AOPRD1 | |
| Norchlorcyclizine SCHEMBL7993069 | 0.91 | CYP2D6 (0.71) | CYP2D6CYP19A1MEN1KMT2AOPRD1 | |
| Norchlorcyclizine SCHEMBL2426579 | 0.90 | CYP2D6 (0.69) | CYP2D6CYP19A1MEN1KMT2AOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112585139-B | Naphthyridinone compounds as T cell activators | 百时美施贵宝公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-112585139-A | Nalidinone compounds as T cell activators | 百时美施贵宝公司 | 2021-03-30 | — | — | CN | disclosed |
| US-10322122-B2 | Methods and compositions for treating degenerative and ischemic disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2019-06-18 | — | — | US | disclosed |
| EP-2429530-B1 | (S)-MECLIZINE FOR TREATING ISCHAEMIA-REPERFUSION INJURY | MASSACHUSETTS GEN HOSPITAL (US) | 2018-11-07 | — | — | EP | disclosed |
| US-20180071279-A1 | METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC DISORDERS | THE GENERAL HOSPITAL CORPORATION | 2018-03-15 | — | — | US | disclosed |
| US-20170001988-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2017-01-05 | — | — | US | disclosed |
| US-20170001988-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2017-01-05 | — | — | US | disclosed |
| US-20160324850-A1 | Methods and Compositions for Treating Degenerative and Ischemic Disorders | THE GENERAL HOSPITAL CORPORATION | 2016-11-10 | — | — | US | disclosed |
| CN-106029060-A | piperidine and piperidine derivatives and their use in the treatment of viral infections and cancer | 美国卫生和人力服务部 | 2016-10-12 | — | — | CN | disclosed |
| US-9399032-B2 | Methods and compositions for treating degenerative and ischemic disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2016-07-26 | — | — | US | disclosed |
| WO-2015080949-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-06-04 | — | — | WO | disclosed |
| US-8350031-B2 | Processes for the synthesis of levocetirizine and intermediates for use therein | CIPLA LIMITED (IN) | 2013-01-08 | — | — | US | disclosed |
| US-8350031-B2 | Processes for the synthesis of levocetirizine and intermediates for use therein | CIPLA LIMITED (IN) | 2013-01-08 | — | — | US | disclosed |
| US-20120136007-A1 | METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC DISORDERS | THE GENERAL HOSPITAL CORPORATION (US) | 2012-05-31 | — | — | US | disclosed |
| US-20110184174-A1 | Processes for the Synthesis of Levocetirizine and Intermediates for Use Therein | CIPLA LIMITED (IN) | 2011-07-28 | — | — | US | disclosed |
| US-20110184174-A1 | Processes for the Synthesis of Levocetirizine and Intermediates for Use Therein | CIPLA LIMITED (IN) | 2011-07-28 | — | — | US | disclosed |
| WO-2009147389-A2 | PROCESSES FOR THE SYNTHESIS OF LEVOCETIRIZINE AND INTERMEDIATES FOR USE THEREIN | CIPLA LIMITED (IN) | 2009-12-10 | — | — | WO | disclosed |
| EP-1487810-A2 | 4-(DIARYLMETHYL)-1-PIPERAZINYL DERIVATIVES | Sun Pharmaceuticals Industries Ltd. (IN) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003079970-A2 | 4-(DIARYLMETHYL)-1-PIPERAZINYL DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184174-A1 | Processes for the Synthesis of Levocetirizine and Intermediates for Use Therein | CYP3A5, CYP4A11, IL5 | CYP2D6 66/4885CYP19A1 9/4885MEN1 2753/4885 |
| US-20180071279-A1 | METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC DISORDERS | PINK1, PC, PCK2 | CYP2D6 2734/4885CYP19A1 4099/4885MEN1 2382/4885 |
| US-20170001988-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | NCOR1, RRP15, NCOA1 | CYP2D6 1663/4885CYP19A1 1222/4885MEN1 3157/4885 |
| US-10322122-B2 | Methods and compositions for treating degenerative and ischemic disorders | PINK1, PC, PCK2 | CYP2D6 2734/4885CYP19A1 4099/4885MEN1 2382/4885 |
| US-20120136007-A1 | METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC DISORDERS | PINK1, PC, PCK2 | CYP2D6 2734/4885CYP19A1 4099/4885MEN1 2382/4885 |
| US-20160324850-A1 | Methods and Compositions for Treating Degenerative and Ischemic Disorders | PINK1, PC, PCK2 | CYP2D6 2734/4885CYP19A1 4099/4885MEN1 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.